Skip to main content
    B

    Beam Therapeutics Inc (BEAM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $24.73
    +1.08 (+4.57%)

    Market Cap: $2.46B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(15/27)
    Avg Surprise
    -36.16%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.17
    Range$-1.28 - $-1.05
    13 analysts
    EPS Revisions
    4
    0
    7d
    4
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.18+1.0%
    60d ago$-1.17+0.4%
    30d ago$-1.170.0%
    7d ago$-1.170.0%
    Current$-1.17
    Revenue Consensus
    $10M
    Range$494900 - $32M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.15
    Range$-1.45 - $-0.93
    14 analysts
    Revenue Consensus
    $9M
    Range$-39383820 - $56M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.15---
    Sep 26EST
    		-$-1.17---
    Jun 26
    Reported Aug 4
    		$-1.18$1.00-218.00%Miss-18.0%
    Mar 26
    Reported May 7
    		$-0.91$-1.01+9.90%Beat+26.6%
    Dec 25
    Reported Feb 24
    		$2.33$-1.01+330.69%Beat+313.8%
    Sep 25
    Reported Nov 4
    		$-1.10$-1.01-8.91%Miss+6.0%
    Jun 25
    Reported Aug 5
    		$-1.00$-1.09+8.26%Beat+9.9%
    Mar 25
    Reported May 6
    		$-1.24$-1.17-5.98%Miss-2.5%
    Dec 24
    Reported Feb 25
    		$-1.09$-1.22+10.35%Beat-163.0%
    Sep 24
    Reported Nov 5
    		$-1.17$-1.18+0.85%Beat+4.1%
    Jun 24
    Reported Aug 6
    		$-1.11$-1.12+0.89%Beat-2.8%
    Mar 24
    Reported May 7
    		$-1.21$-1.39+12.95%Beat+9.0%
    Dec 23
    Reported Feb 27
    		$1.73$-1.01+271.29%Beat+420.4%
    Sep 23
    Reported Nov 8
    		$-1.22$-1.27+3.94%Beat+21.8%
    Jun 23
    Reported Aug 8
    		$-1.08$-1.38+21.74%Beat-5.9%
    Mar 23
    Reported May 10
    		$-1.33$-1.30-2.31%Miss-31.7%
    Dec 22
    Reported Feb 28
    		$-0.54N/A+59.40%Beat+43.2%
    Sep 22
    Reported Nov 7
    		$-1.56$-1.09-43.12%Miss-271.4%
    Jun 22
    Reported Aug 9
    		$-1.02$-1.02+0.00%Beat+17.1%
    Mar 22
    Reported May 9
    		$-1.01$-1.34+24.63%Beat+69.9%
    Dec 21
    Reported Feb 28
    		$-0.95$-1.03+7.77%Beat+43.8%
    Sep 21
    Reported Nov 8
    		$-0.42$-0.72+41.67%Beat+39.1%
    Jun 21
    Reported Aug 10
    		$-1.23$-0.74-66.22%Miss-78.3%
    Mar 21
    Reported May 11
    		$-3.35$-0.75-346.67%Miss-225.2%
    Dec 20
    Reported Mar 15
    		$-1.69$-0.67-152.24%Miss+62.2%
    Sep 20
    Reported Nov 10
    		$-0.69$-0.54-27.78%Miss+52.1%
    Jun 20
    Reported Aug 12
    		$-0.69$-0.51-35.29%Miss-53.3%
    Mar 20
    Reported May 12
    		$-1.03$-0.48-114.58%Miss-
    Dec 19
    Reported Feb 7
    		$-4.47$-0.52-759.62%Miss-
    Sep 19
    Reported Nov 27
    		$-1.44$0.00N/AMiss-
    Jun 19
    Reported Sep 27
    		$-0.45$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-28.76EV/EBITDAN/A
    Price/FCF-6.92xFCF Yield-14.45%
    Profitability
    Profit Margin-55.40%Operating Margin-25827.00%
    ROE-8.18%ROIC-25.65%
    Financial Health
    Debt/Equity0.10xInterest Coverage9.77x
    Current Ratio14.57xQuick Ratio14.57x
    Trading Statistics
    Beta2.20Avg Volume1.86M
    52-Week High$38.2652-Week Low$20.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$24.84
    SMA 20$24.77
    SMA 50$26.34
    SMA 200$28.37
    EMA 10$24.68
    EMA 20$24.95
    EMA 50$26.10
    EMA 200$27.06

    MACD

    Line: -0.45Signal: -0.54Hist: 0.09

    ADX

    ADX: 11.7+DI: 24.0-DI: 22.9

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down16.0
    PSAR$26.57

    Bollinger Bands

    Upper Band$25.91
    Lower Band$23.64
    %B Position917%(Upper)
    Band Width0.48

    RSI (14-Day)

    Neutral
    47.1

    Momentum Oscillators

    Stoch %K28.2
    Stoch %D37.0
    Williams %R-59.1
    ROC (10d)1.4%
    Momentum0.34
    CCI (20d)-66.9
    MFI (14d)51.1

    Volatility Measures

    ATR (14d)$1.39(5.6%)
    StdDev (20d)0.57
    Hist Vol43.9%(High)

    Volume Flow

    VWAP$24.30
    OBV2.5M
    AD Line-42.9M
    CMF (20d)0.041

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio1.0x
    VWMA (20d)$24.81

    Pivot Points

    R3$25.16
    R2$24.71
    R1$24.18
    Pivot Point$23.73
    S1$23.20
    S2$22.75
    S3$22.22

    Advanced Oscillators

    TSI-10.55
    Ultimate Osc51.3
    KST-56.99

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$490,000$31.74M$114.11M$9.70M$8.47M$7.47M$30.07M$14.27M$11.77M$7.41M$316.19M$17.19M
    Cost of Revenue$0$0$5.67M$0$0$0$101.44M$0$0$0$140.08M$0
    Gross Profit$490,000$31.74M$114.11M$9.70M$8.47M$7.47M$30.07M$14.27M$11.77M$7.41M$316.19M$17.19M
    Operating Expenses$127.04M$138.95M$131.50M$136.51M$128.62M$126.78M$130.08M$120.80M$116.67M$111.54M$183.33M$125.46M
    R&D$95.10M$104.52M$99.28M$109.77M$101.76M$98.82M$101.44M$94.26M$87.04M$84.82M$140.08M$100.05M
    SG&A$31.95M$34.43M$32.28M$26.74M$26.86M$27.94M$28.66M$26.52M$29.63M$26.72M$43.26M$25.41M
    Operating Income$-126,553,000$-107,215,000$-17,445,000$-126,811,000$-120,151,000$-119,286,000$-100,037,000$-106,504,000$-104,895,000$-104,132,000$132.86M$-108,267,000
    Interest Income$455,000$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-7,487,000$-9,867,000$-10,640,000$-10,903,000$-12,326,000$-9,864,000$-10,928,000$-12,127,000$-14,190,000$-11,849,000$-12,064,000$-12,698,000
    Income Before Tax$-122,678,000$-94,318,000$244.30M$-112,728,000$-102,138,000$-108,330,000$-90,354,000$-96,668,000$-91,012,000$-98,669,000$47.70M$-96,088,000
    Income Tax Expense$0$0$0$0$0$0$0$0$39,000$0$0$0
    Net Income$-122,678,000$-94,318,000$244.30M$-112,728,000$-102,138,000$-108,330,000$-90,354,000$-96,668,000$-91,051,000$-98,669,000$142.80M$-96,088,000
    EBITDA$-127,751,000$-101,308,000$-19,134,000$-122,304,000$-113,544,000$-116,488,000$-100,506,000$-108,916,000$-105,552,000$-111,663,000$130.11M$-111,483,000
    EBIT$-130,620,000$-104,185,000$-21,544,000$-123,631,000$-114,464,000$-118,167,000$-101,309,000$-108,768,000$-105,202,000$-110,518,000$132.10M$-108,786,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BEAM

    News

    Form 144 BEAM THERAPEUTICS INC. For: 16 October By Investing.com

    This article announces the filing of Form 144 for Beam Therapeutics Inc. on October 16. It is a brief, unembellished report by Investing.com...

    Investing.com India•10/16/26•Neutral

    A 25,000-share sale is planned by Beam Therapeutics (BEAM) officer and director John M. Evans.

    Beam Therapeutics officer and director John M. Evans plans to sell 25,000 common shares with an aggregate market value of $589,150.00. The shares were acquired through a stock option exercise and will be sold via Morgan...

    Stock Titan•10/15/26•Neutral

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

    Pomerantz LLP has announced an investigation into Beam Therapeutics Inc. (NASDAQ: BEAM) on behalf of investors...

    PR Newswire•10/15/26•Bearish

    HC Wainwright & Co. reiterates Buy rating on Beam Therapeutics, $80 price target

    HC Wainwright & Co. has reiterated a Buy rating for Beam Therapeutics (BEAM) with an $80 price target, suggesting a significant upside. This positive outlook is driven by favorable early clinical data from BEAM-301...

    TradingView•10/15/26•Bullish

    Law firm investigates Beam Therapeutics over potential securities fraud after clinical trial data causes stock drop

    Pomerantz LLP has initiated an investigation into Beam Therapeutics Inc. for potential securities fraud following a nearly 10% stock drop. This investigation comes after the company released updated clinical trial data...

    Pluang•10/13/26•Bearish

    BEAM Valuation and Fair Value

    P/E
    -28.8x
    P/FCF
    -6.9x
    P/B
    2.4x
    See GNG's fair value

    BEAM Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -25827.0%
    Net margin
    -55.4%
    ROIC
    -25.6%
    ROE
    -8.2%
    FCF margin
    -238.9%
    FCF yield
    -14.4%

    BEAM Competitors

    CompanyTicker
    Sellas Life Sciences Group IncSLS
    Maravai Lifesciences Holdings IncMRVI
    Zai Lab LtdZLAB
    MBX Biosciences, Inc. Common StockMBX
    Clover Health Investments CorpCLOV
    HUTCHMED DRCHCM
    Guardian Pharmacy Services, Inc.GRDN
    89bio IncETNB

    Sector: Healthcare

    BEAM Analyst Ratings

    Consensus
    Buy
    Analysts
    15
    Strong Buy
    1
    Buy
    12
    Hold
    2
    Sell
    0
    Strong Sell
    0

    BEAM Bull Case vs Bear Case

    Bull case

    • 86.7% of BEAM's analyst ratings are Buy or Strong Buy.

    Bear case

    • BEAM has a -55.4% net profit margin.
    • BEAM's quarterly revenue changed -94.2% year over year.

    BEAM Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    15.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.17
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 5 down

    Frequently Asked Questions About BEAM

    Does BEAM pay dividends?

    Beam Therapeutics Inc (BEAM) does not currently pay a regular dividend.

    What is BEAM's market cap?

    Beam Therapeutics Inc (BEAM) has a market capitalization of $2.46B with a current stock price of $24.73.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In